Virtus Biotech Clinical Trials ETF (NY:BBC)
Price and Volume
Detailed Quote| Volume | 18,257 |
| Open | 55.56 |
| Bid (Size) | 53.25 (500) |
| Ask (Size) | 55.37 (200) |
| Prev. Close | 55.34 |
| Today's Range | 53.18 - 55.56 |
| 52wk Range | 22.43 - 56.18 |
| Shares Outstanding | 4,000 |
| Dividend Yield | 1.23% |
Top News
More News
Performance
More News
Read More
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
February 27, 2026
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
February 11, 2026
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
January 07, 2026
Why Is uniQure Stock Skyrocketing On Tuesday? ↗
December 10, 2024
5 ETFs Riding High On The Biotech Comeback ↗
July 09, 2022
Biotech ETF Tops in June: 5 Stocks That Outperform ↗
June 30, 2022
4 Sector ETFs That Survived Market Turmoil in June ↗
June 29, 2022
Frequently Asked Questions
Is Virtus Biotech Clinical Trials ETF publicly traded?
Yes, Virtus Biotech Clinical Trials ETF is publicly traded.
What exchange does Virtus Biotech Clinical Trials ETF trade on?
Virtus Biotech Clinical Trials ETF trades on the New York Stock Exchange
What is the ticker symbol for Virtus Biotech Clinical Trials ETF?
The ticker symbol for Virtus Biotech Clinical Trials ETF is BBC on the New York Stock Exchange
What is the current price of Virtus Biotech Clinical Trials ETF?
The current price of Virtus Biotech Clinical Trials ETF is 53.29
When was Virtus Biotech Clinical Trials ETF last traded?
The last trade of Virtus Biotech Clinical Trials ETF was at 08/28/26 08:00 PM ET
What is the market capitalization of Virtus Biotech Clinical Trials ETF?
The market capitalization of Virtus Biotech Clinical Trials ETF is 213.18K
How many shares of Virtus Biotech Clinical Trials ETF are outstanding?
Virtus Biotech Clinical Trials ETF has 213K shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.